• Understanding Alpha‑1
• Treating Alpha‑­1
  • Augmentation Therapy
  • Other Supportive Measures
• The Zemaira Difference
• Talking with your doctor
  • Do I have Alpha‑1?
• For Healthcare Professionals
  • Testing and Diagnosis
  • The Benefits of Zemaira
  • Resources for HCPs
• CAREZ™

• Understanding Alpha‑1
• Treating Alpha‑­1
• The Zemaira Difference
• Talking with your doctor
• For Healthcare Professionals
  • Testing and Diagnosis
    • ATS/ERS Guidelines
    • Alpha‑1 Diagnostic Tests
    • Order Test Kits
  • The Benefits of Zemaira
  • Resources for HCPs
• CAREZ™

Diagnostic Tests

Accurate Alpha-1 diagnosis may require three levels of testing

Specific protein- and molecular-based tests are used to achieve an accurate diagnosis of Alpha-1 and include three levels of testing that yield both quantitative and qualitative results¹¹:

• Immunoassay
• Phenotype
• Genotype

Depending on the results obtained, not all of these tests will be required.¹¹

• Quantitative immunoassay will generally be the first test ordered to determine whether alpha₁ antitrypsin levels are below the normal range
• All three tests may be used to obtain a definitive diagnosis

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira^® is indicated for chronic augmentation and maintenance therapy for adults with alpha₁-proteinase inhibitor (A₁-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A₁-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.